CYT004-MelQbG10: Phase IIa data

Pooled data from 3 open-label Phase IIa trials in a total of 22 patients showed that all 3 doses of CYT004-MelQbG10 were safe and produced T cell responses in 14 patients. Also, 6 of 7 patients who en...